# Arrowhead Pharmaceuticals, Inc.: financial statements, quarterly

ARWR · Nasdaq · CIK 879407 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/arwr.md) · [Financials](/companies/arwr/financials.md) · [Filings](/companies/arwr/filings.md) · [Insiders](/companies/arwr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/arwr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [16.1 d](/filings/0000879407-25-000029.md) | [3.6](/filings/0001628280-25-004634.md) | [0.0](/filings/0001628280-25-024666.md) | [0.0](/filings/0001628280-25-038858.md) | [0.0 d](/filings/0000879407-25-000029.md) | [2.5](/filings/0000879407-26-000034.md) | [543](/filings/0000879407-26-000047.md) | [27.8](/filings/0000879407-26-000057.md) | [256 d](/filings/0000879407-25-000029.md) | [264](/filings/0000879407-26-000034.md) | [73.7](/filings/0000879407-26-000047.md) | [75.3](/filings/0000879407-26-000057.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | [137](/filings/0000879407-26-000034.md) | [133](/filings/0000879407-26-000047.md) | [162](/filings/0000879407-26-000057.md) | [175 d](/filings/0000879407-25-000029.md) | [177](/filings/0000879407-26-000034.md) | [173](/filings/0000879407-26-000047.md) | [198](/filings/0000879407-26-000057.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | [28.4](/filings/0000879407-26-000047.md) | [30.9](/filings/0000879407-26-000057.md) | not reported | not reported | [41.7](/filings/0000879407-26-000047.md) | [47.1](/filings/0000879407-26-000057.md) |
| Operating income | $m | [(108) d](/filings/0000879407-25-000029.md) | [(137)](/filings/0001628280-25-004634.md) | [(126)](/filings/0001628280-25-024666.md) | [(176)](/filings/0001628280-25-038858.md) | [(162) d](/filings/0000879407-25-000029.md) | [(161)](/filings/0000879407-26-000034.md) | [381](/filings/0000879407-26-000047.md) | [(166)](/filings/0000879407-26-000057.md) | [44.1 d](/filings/0000879407-25-000029.md) | [40.8](/filings/0000879407-26-000034.md) | [(141)](/filings/0000879407-26-000047.md) | [(170)](/filings/0000879407-26-000057.md) |
| Interest expense | $m | [5.3 d](/filings/0001628280-23-040219.md) | [5.4](/filings/0001628280-24-003492.md) | [7.2](/filings/0001628280-24-022215.md) | [5.1](/filings/0001628280-25-038858.md) | [14.6 d](/filings/0000879407-25-000029.md) | [21.6](/filings/0000879407-26-000034.md) | [21.6](/filings/0000879407-26-000047.md) | [24.4](/filings/0000879407-26-000057.md) | [21.7 d](/filings/0000879407-25-000029.md) | [22.5](/filings/0000879407-26-000034.md) | [23.8](/filings/0000879407-26-000047.md) | [24.6](/filings/0000879407-26-000057.md) |
| Income tax | $m | [2.0 d](/filings/0000879407-25-000029.md) | [(3.3)](/filings/0001628280-25-004634.md) | [0.0](/filings/0001628280-25-024666.md) | [0.0](/filings/0001628280-25-038858.md) | [0.5 d](/filings/0000879407-25-000029.md) | [0.1](/filings/0000879407-26-000034.md) | [1.8](/filings/0000879407-26-000047.md) | [(0.4)](/filings/0000879407-26-000057.md) | [20.0 d](/filings/0000879407-25-000029.md) | [0.0](/filings/0000879407-26-000034.md) | [0.0](/filings/0000879407-26-000047.md) | [0.0](/filings/0000879407-26-000057.md) |
| Net income | $m | [(110) d](/filings/0000879407-25-000029.md) | [(133)](/filings/0001628280-25-004634.md) | [(125)](/filings/0001628280-25-024666.md) | [(171)](/filings/0001628280-25-038858.md) | [(171) d](/filings/0000879407-25-000029.md) | [(173)](/filings/0000879407-26-000034.md) | [370](/filings/0000879407-26-000047.md) | [(175)](/filings/0000879407-26-000057.md) | [(23.8) d](/filings/0000879407-25-000029.md) | [30.8](/filings/0000879407-26-000034.md) | [(133)](/filings/0000879407-26-000047.md) | [(194)](/filings/0000879407-26-000057.md) |
| Diluted EPS | $ per share | not reported | [(1.24)](/filings/0001628280-25-004634.md) | [(1.02)](/filings/0001628280-25-024666.md) | [(1.38)](/filings/0001628280-25-038858.md) | not reported | [(1.39)](/filings/0000879407-26-000034.md) | [2.75](/filings/0000879407-26-000047.md) | [(1.26)](/filings/0000879407-26-000057.md) | not reported | [0.22](/filings/0000879407-26-000034.md) | [(0.93)](/filings/0000879407-26-000047.md) | [(1.36)](/filings/0000879407-26-000057.md) |
| Basic EPS | $ per share | not reported | [(1.24)](/filings/0001628280-25-004634.md) | [(1.02)](/filings/0001628280-25-024666.md) | [(1.38)](/filings/0001628280-25-038858.md) | not reported | [(1.39)](/filings/0000879407-26-000034.md) | [2.78](/filings/0000879407-26-000047.md) | [(1.26)](/filings/0000879407-26-000057.md) | not reported | [0.22](/filings/0000879407-26-000034.md) | [(0.93)](/filings/0000879407-26-000047.md) | [(1.36)](/filings/0000879407-26-000057.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [58.2](/filings/0001628280-24-003492.md) | [128](/filings/0001628280-24-022215.md) | [69.4](/filings/0001628280-24-036104.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [416](/filings/0001628280-24-049277.md) | [238](/filings/0001628280-24-003492.md) | [542](/filings/0001628280-24-022215.md) | [450](/filings/0001628280-24-036104.md) | [695](/filings/0000879407-25-000029.md) | [571](/filings/0001628280-25-004634.md) | [1,135](/filings/0001628280-25-024666.md) | [947](/filings/0001628280-25-038858.md) | [951](/filings/0000879407-26-000057.md) | [1,174](/filings/0000879407-26-000034.md) | [1,840](/filings/0000879407-26-000047.md) | [1,671](/filings/0000879407-26-000057.md) |
| Total assets | $m | [766](/filings/0001628280-24-049277.md) | [626](/filings/0001628280-24-003492.md) | [955](/filings/0001628280-24-022215.md) | [884](/filings/0001628280-24-036104.md) | [1,140](/filings/0000879407-25-000029.md) | [1,014](/filings/0001628280-25-004634.md) | [1,573](/filings/0001628280-25-024666.md) | [1,381](/filings/0001628280-25-038858.md) | [1,385](/filings/0000879407-26-000057.md) | [1,604](/filings/0000879407-26-000034.md) | [2,268](/filings/0000879407-26-000047.md) | [2,112](/filings/0000879407-26-000057.md) |
| Current liabilities | $m | [105](/filings/0001628280-24-049277.md) | [63.7](/filings/0001628280-24-003492.md) | [65.2](/filings/0001628280-24-022215.md) | [96.7](/filings/0001628280-24-036104.md) | [103](/filings/0000879407-25-000029.md) | [93.8](/filings/0001628280-25-004634.md) | [221](/filings/0001628280-25-024666.md) | [195](/filings/0001628280-25-038858.md) | [195](/filings/0000879407-26-000057.md) | [347](/filings/0000879407-26-000034.md) | [295](/filings/0000879407-26-000047.md) | [283](/filings/0000879407-26-000057.md) |
| Shareholders' equity | $m | [271](/filings/0001628280-24-049277.md) | [160](/filings/0001628280-24-003492.md) | [484](/filings/0001628280-24-022215.md) | [331](/filings/0001628280-24-036104.md) | [185](/filings/0000879407-25-000029.md) | [52.6](/filings/0001628280-25-004634.md) | [683](/filings/0001628280-25-024666.md) | [522](/filings/0001628280-25-038858.md) | [466](/filings/0000879407-26-000057.md) | [568](/filings/0000879407-26-000034.md) | [614](/filings/0000879407-26-000047.md) | [466](/filings/0000879407-26-000057.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(25.9) d](/filings/0000879407-25-000029.md) | [(118)](/filings/0001628280-25-004634.md) | [(92.4) d](/filings/0001628280-25-024666.md) | [(115) d](/filings/0001628280-25-038858.md) | [(137) d](/filings/0000879407-25-000029.md) | [(146)](/filings/0000879407-26-000034.md) | [460 d](/filings/0000879407-26-000047.md) | [(155) d](/filings/0000879407-26-000057.md) | [20.5 d](/filings/0000879407-25-000029.md) | [13.5](/filings/0000879407-26-000034.md) | [84.4 d](/filings/0000879407-26-000047.md) | [(177) d](/filings/0000879407-26-000057.md) |
| Capital expenditure | $m | [63.9 d](/filings/0000879407-25-000029.md) | [68.7](/filings/0001628280-25-004634.md) | [34.1 d](/filings/0001628280-25-024666.md) | [14.4 d](/filings/0001628280-25-038858.md) | [24.3 d](/filings/0000879407-25-000029.md) | [7.5](/filings/0000879407-26-000034.md) | [5.3 d](/filings/0000879407-26-000047.md) | [2.4 d](/filings/0000879407-26-000057.md) | [7.5 d](/filings/0000879407-25-000029.md) | [2.1](/filings/0000879407-26-000034.md) | [2.6 d](/filings/0000879407-26-000047.md) | [3.9 d](/filings/0000879407-26-000057.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [106](/filings/0001628280-24-003492.md) | [108](/filings/0001628280-24-022215.md) | [107](/filings/0001628280-24-036104.md) | [107](/filings/0001628280-25-004634.md) | [123](/filings/0001628280-25-024666.md) | [124](/filings/0001628280-25-038858.md) | [125](/filings/0000879407-26-000034.md) | [134](/filings/0000879407-26-000047.md) | [139](/filings/0000879407-26-000057.md) | [141](/filings/0000879407-26-000034.md) | [142](/filings/0000879407-26-000047.md) | [143](/filings/0000879407-26-000057.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 141,254,467 at 2026-07-30, from the cover of the [10-Q filed 2026-08-04](/filings/0000879407-26-000057.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.